BPC-157
Body Protection Compound-157
BPC-157 is a 15-amino-acid partial sequence derived from human gastric juice proteins. It has attracted significant preclinical research interest for its effects on musculoskeletal tissue repair, gastrointestinal healing, and nitric oxide pathway modulation.
Mechanism of Action
BPC-157 exerts its primary effects through upregulation of the nitric oxide (NO) signalling pathway. By promoting NO synthase activity, it drives vasodilation and angiogenesis at injury sites, accelerating the delivery of repair-critical growth factors.
Research also suggests BPC-157 interacts with the VEGFR2 receptor (vascular endothelial growth factor receptor), promoting new blood vessel formation in damaged connective tissue. This mechanism is thought to underpin its observed effects on tendon, ligament, and muscle repair in animal models.
Additionally, BPC-157 has been shown to modulate dopaminergic and serotonergic signalling in the central nervous system in rodent studies, which may partially explain reported effects on stress tolerance and gut-brain axis function.
Research Evidence
The majority of BPC-157 research is preclinical (animal and in vitro). No large-scale randomised controlled trials in humans have been published as of 2026. The FDA's 2024 assessment noted insufficient human safety and efficacy data to support therapeutic use, removing it from permissible compounding lists. However, the breadth of animal model evidence across multiple organ systems has sustained research interest.
BPC-157 Accelerates Tendon Healing in Rat Achilles Tendon Transection Model
Subcutaneous BPC-157 significantly accelerated gross and histological healing of complete Achilles tendon transections, with improved tendon organisation versus controls at both 1- and 2-week timepoints.
Gastric Pentadecapeptide BPC-157 in Inflammatory Bowel Disease Models
Oral and parenteral BPC-157 reduced mucosal inflammation and promoted epithelial regeneration in both TNBS- and cysteamine-induced ulceration models, suggesting GI protective properties independent of route.
BPC-157 and NO-System Interactions in Wound Healing
Comprehensive review confirming NO pathway centrality in BPC-157 wound healing effects; noted synergistic action with L-arginine and antagonism with NOS inhibitors, confirming mechanism specificity.
Typical Research Protocol
No established human therapeutic dose exists. Ranges cited are derived from animal-to-human dose extrapolations used in research contexts. Oral BPC-157 has been studied for GI applications; stability in GI tract is debated.
Safety Profile
Reported Side Effects
- Injection site redness or bruising
- Mild nausea (oral form)
- Transient dizziness
- Warmth at injection site
Contraindications
- Active malignancy (theoretical growth stimulation concern)
- Pregnancy (no safety data)
- Concurrent anticoagulant therapy (caution)
- Known peptide hypersensitivity
Common Research Stacks
Frequently Asked Questions
Is BPC-157 legal to purchase?
In most countries, BPC-157 is not approved for human therapeutic use. In the US, it was removed from permissible compounding lists by the FDA in 2024. It remains available as a research chemical from laboratory suppliers in many jurisdictions. Always verify the current legal status in your country.
Does BPC-157 work orally?
Oral BPC-157 has been studied specifically for gastrointestinal conditions, where local gut exposure is the target. Systemic bioavailability via oral administration is debated — some researchers argue the peptide is degraded in the GI tract before absorption, while others cite evidence of partial absorption. Subcutaneous injection is generally considered the more reliable route for systemic effects.
How long does BPC-157 take to show effects?
In animal models, observable tissue healing improvements were noted within 1–2 weeks. In research contexts, protocols typically run 4–12 weeks. Individual response variability and the nature of the injury being studied significantly affect timelines.
Can BPC-157 be used for gastrointestinal conditions?
Yes — GI protection is one of BPC-157's most consistent findings. It heals gastric ulcers, reduces colitis markers, and protects the gut lining across multiple animal models. Oral administration is specifically studied for GI applications since direct mucosal contact may be the active mechanism rather than systemic absorption.
What is the difference between BPC-157 and Pentadeca Arginate (PDA)?
Pentadeca Arginate (PDA) is a modified form of BPC-157 with an arginine substitution that improves stability and does not require refrigeration. PDA also has enhanced nitric oxide pathway activity. Both share the 15-amino-acid backbone and similar mechanisms; PDA is sometimes chosen when storage or shipping conditions make refrigeration impractical.
Should BPC-157 be injected near the injury site?
Local injection near the injury is common practice — BPC-157's angiogenic and NO pathway effects are concentrated in the area surrounding the injection site, which provides the most targeted repair signal. For systemic or GI applications, abdominal SC injection is practical. There is no definitive human data proving local superiority over remote injection.
Key Research References
- Sikiric P et al. (2010). Stable gastric pentadecapeptide BPC-157: novel therapy in gastrointestinal tract. Curr Pharm Des.
- Gwyer D et al. (2019). Gastric pentadecapeptide body protection compound BPC-157. Curr Pharm Des.
- Chang CH et al. (2011). Bone healing effects of BPC-157. J Orthop Res.
Explore more Recovery research compounds
Browse Recovery →